There is no published price list for registering a drug in China, and anyone who quotes you one number without first asking what the product is, has already given you the wrong answer. The cost and the timeline are both set by three things: the product class, the data you already hold, and whether you register through a local holder or as a foreign applicant.
The stages, in order
Registration is a sequence, and the formal review is only the middle of it. Most of the elapsed time sits before and after the regulator's clock.
| Stage | What happens | Where the time goes |
|---|---|---|
| Dossier preparation | Assemble quality, safety and efficacy data to the Chinese format | Translation, gap analysis, reformatting — often the longest single block |
| Pre-clinical / clinical data | Supply the studies the NMPA requires for the product class | Running new studies adds months to years |
| Formal submission | Lodge the application with the NMPA | Application fee and acceptance |
| Review & supplementary responses | Regulator review, questions, your responses | Review clock plus response windows |
| Approval & post-approval | Approval number granted, then GMP and batch-release obligations | Renewal every five years, ongoing compliance |
Why the product class changes everything
A chemical generic with established data can move through review in roughly one to three years. A biological product — and especially a plasma-derived product — is a different proposition: the quality, safety and often clinical requirements are heavier, so both the preparation and the review stretch longer.
| Factor | Chemical / generic | Biological (incl. plasma-derived) |
|---|---|---|
| Data burden | Often bridged from reference data | Substantial quality and safety data |
| Typical review window | Roughly 1–3 years | Longer, product-dependent |
| Cost drivers | Testing, translation, fees | Studies, testing, local agent, longer review |
| Post-approval | Standard GMP | State batch release per lot |
Where the money actually goes
The official application fee is the smallest line item. The real budget is consumed by the work around the application:
- Studies and testing. The clinical, quality and safety data the NMPA requires for the product class.
- Translation and formatting. A dossier must be presented in Chinese, to the Chinese format — this is volume work, not a single task.
- The local holder or agent. A foreign applicant registers through a local marketing authorisation holder or licensed agent that can hold the registration and answer the regulator.
- Legal and regulatory counsel. Managing the review, the responses, and the renewal obligations.
Plan for the cost of the data and the local holder, not just the fee. The application fee is the part everyone knows; the data and the holder are the parts that determine whether the registration ever happens.
How this connects to exporting from China
This page is about registering a drug in China. Exporting an already-registered Chinese product is a shorter, different path — and it is the one most of our buyers are actually on. The two are easily confused:
- Registering in China = a multi-year, data-heavy project, described above.
- Exporting a registered Chinese product = confirming the approval number, the batch release and the CPP, then meeting the importing country's rules.
If your goal is to buy an already-approved plasma product and import it, the timeline that matters is the import licence in your country, not the NMPA registration clock. That distinction is worth getting straight before you budget either way.
Frequently asked questions
How long does NMPA registration actually take?
It depends on the product class. A chemical or generic can take roughly one to three years of regulatory review; a biological product is longer and more data-heavy. The review clock is not the whole story — dossier preparation, studies and supplementary responses often take more time than the formal review.
What does it cost to register a drug in China?
There is no single figure. The official application fee is modest; the real cost is in the studies, testing, translation, legal and local-agent work. A biological product costs far more than a simple generic because of the clinical and quality data required.
Do I need a local agent to register in China?
Yes, in practice. A foreign applicant typically registers through a local marketing authorisation holder or a licensed agent that can hold the registration and respond to the NMPA. The holder is the legal entity named on the approval number.
Is the timeline for a biological product different from a chemical one?
Yes. Biological products — including plasma-derived products — face stricter quality, safety and often clinical requirements, so both the preparation and the review take longer. The registration path is not interchangeable with a chemical drug's path.
What happens after the approval number is granted?
The registration runs five years and must be renewed. After approval, the holder still needs to meet batch release and ongoing GMP obligations, and each specific lot of a plasma product must be released by the state before sale.
Where to go next
- Certificate of Pharmaceutical Product — the registration evidence an importing regulator asks for.
- Supplier due diligence checklist — the checks before you commit.
- Product index — the already-registered products we export, with their approval references.